A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are significant causes of severe respiratory illness in vulnerable populations.
• The pre-fusion form of the viral Fusion (F) protein is a key target for neutralizing antibodies and vaccine development.

Purpose of the Study:

• To design and evaluate the immunogenicity and protective efficacy of a novel chimeric fusion protein (RHMS-1) targeting both RSV F and hMPV F.
• To assess RHMS-1's ability to induce cross-protective immunity against two major respiratory viruses using a single antigen.

Main Methods:

• Development of a trimeric recombinant chimeric fusion protein (RHMS-1) incorporating immunodominant epitopes from RSV F and hMPV F.
• Structural analysis using negative-stain electron microscopy to confirm pre-fusion conformation.
• Immunization of mice with RHMS-1, followed by assessment of neutralizing antibody responses and protection against RSV and hMPV challenge.

Main Results:

• RHMS-1 retained key antigenic features of both RSV F and hMPV F pre-fusion proteins.
• Mice immunized with RHMS-1 developed neutralizing antibodies against both viruses.
• Complete protection against RSV and hMPV challenge was observed in immunized mice.

Conclusions:

• RHMS-1 is a promising single-antigen vaccine candidate capable of inducing protective immunity against both RSV and hMPV.
• This chimeric protein strategy offers a potential advantage for developing vaccines against multiple respiratory viruses.
• Further pre-clinical evaluation of RHMS-1 in diverse animal models is warranted.